Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

responses and PFS demonstrated by pixantrone are currently not achievable using standard of care and we would welcome the opportunity to utilize this new drug for the benefit of our patients."

The poster from the conference is available at www.celltherapeutics.com/investor_updates.

To demonstrate that the dose and schedule utilized in the PIX301 trial and proposed for the follow on PIX306 study, is an appropriate dose and exposure for maximizing efficacy while minimizing side effects, the Company had an expert pharmacokinetic exposure safety and efficacy analysis conducted on data from all of its phase I, II and III trials including relapsed refractory patients with solid tumor malignancies. At an investor meeting at ASH those data were presented demonstrating that the dose of pixantrone used in PIX301 and proposed for PIX306 is an appropriate dose demonstrating a significant correlation between exposure to pixantrone and enhanced anti-tumor response (Progression-Free Survival ("PFS")) while minimizing the risk for side effects (neutropenia). The PIX306 trial is currently planned to be a randomized, single-blind study comparing pixantrone + rituximab to combination gemcitabine + rituximab in patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma ("NHL") who are not candidates for myeloablative chemotherapy and stem cell transplant.

A summary status update on the PIX203 front line trial of CPOP-rituximab versus CHOP-rituximab in high risk and elderly DLBCL was also presented at an investigator meeting at ASH. Given that median PFS has not yet been reached for the CPOP-R arm and the median OS has not yet been reached for both treatment arms the Company only provided a brief update on patient demographics, while summarizing key efficacy and safety endpoints of the study. The Company anticipates submitting the PIX203 data for presentation at scientific meetings
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report ... Funding” report provides in-depth analysis of the current ... venture capital segments of the financial industry, bearing ... significant impact on the future of emerging biotechnology ... report identifies regions of the world that are ...
(Date:7/29/2014)... significant technological challenges in their quest to improve ... the James Webb Space Telescope. , The team, ... at NASA,s Goddard Space Flight Center in Greenbelt, ... that is, those activated by applying an ... current technology,s magnetically activated arrays. This advance makes ...
(Date:7/29/2014)... The advanced optical methods and applications ... driving a revolution in the neurosciences were the inspiration ... by SPIE, the international society for optics and ... launch of the BRAIN Initiative in the United States, ... a vision for and provide examples of the impact ...
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... that provides innovative genetic analysis solutions, and Mayo ... laboratory services in the United States ... testing patents and applications. "We have great ... patient care, and we welcome the opportunity to partner ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4
... by SkyPilot Networks at Hamburger University in Oak Brook, Ill., ... rally municipal attendees. He said we need to focus on ... , ,Quinn had some encouraging remarks about keeping the playing ... blockading. He has made this a priority in his job ...
... - Seven emerging companies in the Chippewa Valley are vying ... and, eventually, a needed dose of public awareness as part ... by the Eau Claire Area Economic Development Corporation . ... year, seven applicants have been invited to submit full business ...
... every any doubt, let me assure you that DEMOletter blog readers ... up this space to any reader who had a perspective, opinion, ... Jim Forbes responded. And it seems even Jim prefers the ... again being edited by me. , ,Most of you, I suppose, ...
Cached Biology Technology:Municipal broadband in Illinois: Where are the standards? 2Municipal broadband in Illinois: Where are the standards? 3Municipal broadband in Illinois: Where are the standards? 4Eau Claire business contest down to 7 applicants 2The DEMO Summer Reading List 2The DEMO Summer Reading List 3
(Date:7/29/2014)... Schools of Dentistry (UM SOD) and Medicine (UM ... a five-year $10.7 million grant award from the ... of the National Institutes of Health to study ... (STDs). The grant, which renews a previous $12 ... direction for the research by studying chlamydial and ...
(Date:7/29/2014)... ground breaking new book that brings together two of ... raise the profile of insect fossils through stunning photographs ... Penney and James E Jepson, details the incredible preservation ... setting the scene for what these remarkable fossils can ... even the future of our planet. Like the mosquito ...
(Date:7/28/2014)... new discovery of two additional coral communities showing signs of ... footprint of the 2010 spill in the Gulf of Mexico. ... Fisher, professor of biology at Penn State University. A paper ... corals in the Gulf of Mexico will be published during ... Edition of the journal Proceedings of the National Academy ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... Bluefin Are Skinny DURHAM, N.H. The quality ... Maine has declined significantly since the early 1990s, researchers ... analyzing detailed logbooks from a commercial tuna grader at ... in Fishery Bulletin, indicate potential changes in food sources, ...
... syndrome is a common problem in children 8 years of ... Kingdom, according to a new report from an international team ... to 17 are affected, and a significant proportion of those ... moods. The report appears in the August issue of the ...
... University of Minnesota Medical School and Brain Sciences Center ... noninvasive and painless way to diagnose complex brain diseases. ... of light.The research offers promise for a less-stressful, painless, ... a way to measure the effectiveness of different treatments ...
Cached Biology News:Condition of bluefin tuna in gulf of maine is declining 2Condition of bluefin tuna in gulf of maine is declining 3Restless legs syndrome affects nearly 2 percent of US/UK children 2Restless legs syndrome affects nearly 2 percent of US/UK children 3U of MN researchers discover noninvasive diagnostic tool for brain diseases 2
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
Cell Culture Flask, 75 cm, treated polystyrene...
...
... These 50ml PYREX Delong style shaker ... to provide greater agitation of solutions to ... with rotary or reciprocating shakers. The long ... two-position polypropylene closures. Their uniform wall thickness ...
Biology Products: